AstraZeneca Buys Alexion In $39 Billion-Mega Deal

AstraZeneca Buys Alexion In $39 Billion-Mega Deal

by | Dec 15, 2020 8:14 am | Biotechnology

The global pharmaceutical giant AstraZeneca plc (NYSE: AZN) is back with its fifth deal of the year, and its biggest one at that. AstraZeneca is buying Boston, Massachusetts-based Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for $39 billion. Alexion is a global biopharmaceutical company that has pioneered complement inhibition for a broad spectrum of immune-mediated rare diseases caused by uncontrolled activation of the complement system, a vital part of the immune system. According to the terms of the agreement, Alexion shareholders will receive $60 cash and 2.1243 AstraZeneca American Depositary Shares (ADS) per share (each ADS equals 1/2 AZN share). Based on AstraZeneca’s... Read More »